Concert at the National Alopecia Areata Foundation Research Summit

December 5th, 2018

Concert was pleased to meet with alopecia areata experts and patients at the 2018 National Alopecia Areata Foundation Research Summit, where Dr. James Cassella, our Chief Development Officer, presented an overview of interim results from our ongoing Phase 2 clinical trial of CTP 543, an oral medicine being tested in clinical trials for alopecia areata. Our scientists at Concert have designed CTP-543, which addresses the autoimmune disease process of alopecia areata through a scientific mechanism called JAK1/ JAK2 inhibition.

This Research Summit is hosted by the National Alopecia Areata Foundation (NAAF) every two years to enhance the understanding of alopecia areata and accelerate progress toward treatments.

Back to Top